linjc16/ctgov huggingface dataset:
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients. PURPOSE: This research trial is studying proteins that may promote chemotherapy resistance in samples from patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: Investigate whether changes in prosurvival signaling occur by comparing activation of the signal transducer and activator of transcription-3 (Stat3) and Stat5 pathways in paired diagnostic and relapse samples. Investigate changes in leukemia cell responses to extrinsic cues from the environment change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance. OUTLINE: Cryopreserved samples are analyzed for Stat3 and Stat5 expression by flow cytometry and in vitro chemotherapy sensitivity.

Official Title
-----------------
Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: protein expression analysis
* Other: flow cytometry
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Paired diagnostic and relapsed cryopreserved samples from patients with acute myeloid leukemia PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: protein expression analysis|nan|
|Other: flow cytometry|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Stat3 and Stat5 in paired diagnostic and relapsed AML samples |  |  | 
| Reduction in chemotherapy sensitivity by relapsed samples compared to diagnostic samples |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with del(5q)
Revascularization in Nonagenarian Patients With Critical Lower Limb Ischaemia

Study Overview
=================
Brief Summary
-----------------
The rise in life expectancy implies an increased number of nonagenarian patients who need evaluation for critical lower limb ischaemia (CLI). The study goal is to evaluate whether revascularization techniques in these patients fulfill a set of security and efficacy criteria generated from surgical results in a validated historical cohort.

Official Title
-----------------
Revascularization Results in Nonagenarian Patients With Critical Lower Limb Ischaemia

Conditions
-----------------
Critical Limb Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffering from Critical Limb Ischemia aged 90 year-old or above Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nonagenarian CLI<br>Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence at 30 days of major adverse cardiovascular events (MACE) | Incidence at 30 days of major adverse cardiovascular events (MACE): stroke, myocardial infarction or death by cardiovascular cause, in percentage. | 30 days after the procedure | 
| Incidence at 30 days of major adverse limb events (MALE) | Incidence at 30 days of major adverse limb events (MALE): limb acute ischemia or amputation, in percentage. | 30 days after the procedure | 
| Incidence at 30 days of limb major amputations (MA) | Incidence at 30 days of limb major amputations (MA), in percentage. | 30 days after the procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Limb salvage (LS) | Percentage of revascularized limb which do no require major amputation at 12 months | 12 months after the procedure | 
| Survival | Percentage of patients alive at 12 months | 12 months after the procedure |
Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are: To determine the efficacy of inter pleural analgesia To determine the plasmatic concentration of ropivacaine by inter pleural road

Official Title
-----------------
Randomized Trial to Evaluate the Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery

Conditions
-----------------
Postoperative Pain, Cancer

Intervention / Treatment
-----------------
* Drug: Ropivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thoracotomy for oncology thoracic surgery Secondary or primary cancer American Society of Anesthesiology (ASA) class 1 or 2 Exclusion Criteria: Ropivacaine hypersensibility Psychiatric disorders Incapacity of using visual analog scale

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ropivacaine<br> | Drug: Ropivacaine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the incidence and the score of pain between the patients with ropivacaine and the patients without ropivacaine delivered by inter pleural road |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the morphine consumption during 48 hours |  |  | 
| To determine ropivacaine plasmatic concentration by inter pleural road during first 48 hours |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thoracic surgery, postoperative pain, ropivacaine, inter pleural analgesia
Preventing Behavior Problems in Children With ADHD

Study Overview
=================
Brief Summary
-----------------
This study will determine the effectiveness of a combination of treatments in preventing behaviors that are typically associated with Attention Deficit Hyperactivity Disorder (ADHD) in young children.

Detailed Description
-----------------
Participants are randomly assigned to either a Multi-Setting Early Intervention group or to a Community Intervention group. The Early Intervention group receives parent training and assessment-based behavioral and academic intervention for 1 year, followed by either a high or a low intensity maintenance intervention for an additional 18 months. The Community Intervention group members receive psychotropic medication, special education services, and monthly sessions to obtain information about child development and medical functioning for 2 years. Participants are assessed on six occasions over 4 years. Parents and teachers assess children's behavior, academic performance, and archival data, including medical and school records.

Official Title
-----------------
Prevention of Behavioral Deficits in Young ADHD Children

Conditions
-----------------
Attention Deficit Disorder With Hyperactivity

Intervention / Treatment
-----------------
* Behavioral: Multi-Setting Early Intervention
* Behavioral: Community Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Attention Deficit Hyperactivity Disorder (ADHD) diagnosis Preschool, nursery school, or group daycare enrollment at least 2 days per week Parents who can communicate in English Exclusion Criteria: Plans to move out of the area in the near future Mental retardation, neurological damage, significant motor or physical impairments, or autism or other pervasive developmental disorder Inattentive ADHD or conduct disorder

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Multi-Setting Early Intervention|nan|
|Behavioral: Community Intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation

Study Overview
=================
Brief Summary
-----------------
Currently, standard-of-care tractography is based on information obtained from diffusion tensor imaging (DTI). DTI is a diffusion magnetic resonance imaging (dMRI) technique that is routinely obtained on neurosurgical patients to assist in pre-operative planning. The primary objective of the proposed study is to determine the ability of msHARDI-based tractography to discern fibers in edematous brain regions.

Official Title
-----------------
Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation

Conditions
-----------------
Brain Lesions

Intervention / Treatment
-----------------
* Other: MRI
* Other: Neurocognitive battery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: brain lesions, including but not limited to tumors, epileptic foci, and vascular abnormalities, in or around eloquent brain regions (i.e., motor, language); clinical need for pre-operative 'advanced imaging' (which includes conventional DTI); age between 18-80 years of age; male or female gender. Eloquent regions include: Temporal and frontal lobes (speech/language); bilateral occipital lobes (vision); bilateral parietal lobes (sensation); and bilateral motor cortex (movement). Exclusion Criteria: a contraindication for obtaining an MRI scan (e.g. implanted devices, retrained foreign body) pregnancy absence of the capacity to make medical decisions or provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: MRI|nan|
|Other: Neurocognitive battery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects providing completion of the neurocognitive battery |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eloquent cortex
Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier penetration of the elemene.

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histopathological or cytopathology diagnosis of malignancy heart, liver and renal function is normal Expected survival time is more than 3 months Signed informed consent exclusion Criteria: non cancer patient accepted elemene administration in 1 month Expected survival time is less than 3 months no Signed informed consent heart, liver and renal function is abnormal
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood and cerebrospinal fluid concentration |  | 0，0.25，0.5，1，1.5，2，3，3.5，4，6，8，12 hours post dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elemene, pharmacokinetics, Blood-brain barrier
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate and compare in-tissue performance of OCT scans on the new Optos P200TE, versus the predicate Optos Spectral OCT/SLO device.

Official Title
-----------------
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

Conditions
-----------------
Retinal Disease, Glaucoma

Intervention / Treatment
-----------------
* Device: P200TE
* Device: Spectral OCT/SLO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subjects 18 years of age or older who have full legal capacity to volunteer; Subjects who have signed the informed consent; Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date; Subjects who agree to participate in the study; Subjects with current BSCVA 20/400 or better in the ocular disease study eye(s); Subjects diagnosed with ocular disease including but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Central Serous Retinopathy, Macular Hole, Epiretinal Membrane, Macular Edema, Glaucoma, and others in the retinal disease study eye(s) as confirmed at the study visit or within the past six (6) months. Exclusion Criteria: Subjects unable to tolerate ophthalmic imaging; Subjects with ocular media not sufficiently clear to obtain acceptable OCT images; Subjects without ocular disease in study eye(s), as determined by self-report and/or investigator assessment at the study visit; Subjects with history of leukemia, dementia or multiple sclerosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: All patients<br>All patients will be imaged on the P200TE and Spectral OCT/SLO devices. | Device: P200TE<br>* Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.<br>Device: Spectral OCT/SLO<br>* Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| retinal thickness |  | completion of the study, up to 5 years | 
| Retinal Nerve Fibre Layer Thickness |  | completion of the study, up to 5 years | 
| Optic Nerve Head Topography |  | completion of the study, up to 5 years | 
| Cup/Disc Ratio |  | completion of the study, up to 5 years |
Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if certain findings (blood tests, symptom improvement, etc.) after acute heart failure treatment can identify a group of patients who are safe for early hospital discharge.

Detailed Description
-----------------
A fundamental question faced by physicians treating acute decompensated heart failure (ADHF) is When has treatment worked sufficiently for safe discharge, and who requires further treatment? Patients with ADHF have a high incidence of morbidity and mortality. Current guidelines for emergency department (ED) and hospital disposition of patients with ADHF are based on limited empirical evidence. This creates clinical uncertainty regarding disposition leads to prolonged hospitalizations, higher costs and increased resource consumption. The specific aim of the study is to develop a prediction rule from readily available clinical data to help physicians identify ADHF patients eligible for safe and early discharge from the ED and hospital after treatment is initiated.

Official Title
-----------------
Treatment Endpoints in Acute Decompensated Heart Failure

Conditions
-----------------
Acute Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fulfill the modified Framingham criteria Have baseline data available within 1 hour of initial ED therapy Have previously documented systolic dysfunction (ejection fraction less than 50%) by echocardiogram Willing and able to give informed consent The exclusion criteria are: Patients less than 18 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute heart failure<br>Subjects with an ED diagnosis of acute decompensated heart failure . | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart-failure related adverse events |  | Measured 5 days and 30 days after ED presentation |
Fetal Growth Restriction & Maternal Cardiovascular Risk

Study Overview
=================
Brief Summary
-----------------
To determine whether or not women with a history of having a baby with intrauterine growth retardation (IUGR) was more likely to have risk factors for cardiovascular disease versus women with a pregnancy not complicated by IUGR.

Detailed Description
-----------------
BACKGROUND: Intrauterine growth restriction leads to major neonatal morbidity and mortality. Moreover, recent birth registry studies have suggested that women bearing IUGR babies may have an elevated risk of cardiovascular disease. DESIGN NARRATIVE: This cohort study tested whether exposed women, with a previous intrauterine growth restriction (IUGR) baby, versus unexposed women, with a pregnancy not complicated by IUGR, had elevations in markers of cardiovascular risk. Exposure was defined among a geographically defined cohort as having had a singleton baby in the < 5 %tile of weight for gestational age, in the absence of pre-pregnancy diabetes., hypertension, renal disease, or hypertension in pregnancy; controls had a singleton in the > 20%tile. Four to twelve years postpartum, women were assessed for multiple markers of cardiovascular risk, including blood pressure, lipids, adiposity, glucose and insulin, homocysteine and folate, markers of inflammation, markers of endothelial function, markers of angiogenesis, and markers of vascular function. Data analysis consisted of ANOVA and ANCOVA analyses comparing the outcomes of cardiovascular markers among exposed and unexposed women.

Official Title
-----------------
Fetal Growth Restriction & Maternal Cardiovascular Risk

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: women 4 to 12 years after delivery of singleton infant women who gave birth between 1997 and 2002 at Magee-Womens Hospital in Pittsburgh, Pennsylvania Exclusion criteria: women who had preeclampsia women who had prepregnancy hypertension women who had diabetes women who were currently pregnant or reported a prepregnancy chronic condition
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  | 4 to 12 years after pregnancy | 
| Triglycerides and LDL cholesterol |  | 4 to 12 years after pregnancy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose |  | 4 to 12 years after pregnancy |